Catherine S. Diefenbach, MD

home / authors / catherine-s-diefenbach-md

Articles

Catherine S. Diefenbach, MD, Talks Future of CAR T-cell Therapy Following Liso-Cel Approval in Second-Line LBCL

July 7th 2022

Catherine S. Diefenbach, MD, spoke about refining understanding of CAR T-cell therapies after the approval of lisocabtagene maraleucel for patients with relapsed/refractory large B-cell lymphoma.

$Catherine S. Diefenbach, MD, Discusses Gaps Filled by Approval of Liso-Cel in Second-Line Relapsed/Refractory LBCL$

Catherine S. Diefenbach, MD, Discusses Gaps Filled by Approval of Liso-Cel in Second-Line Relapsed/Refractory LBCL

Catherine S. Diefenbach, MD

July 1st 2022

Catherine S. Diefenbach, MD, spoke about the approval of lisocabtagene maraleucel for patients with relapsed/refractory large B-cell lymphoma who do not have chemotherapy-sensitive disease.

$Catherine S. Diefenbach, MD, Reviews the Approval of Liso-Cel in Second-Line Relapsed/Refractory LBCL$

Catherine S. Diefenbach, MD, Reviews the Approval of Liso-Cel in Second-Line Relapsed/Refractory LBCL

Catherine S. Diefenbach, MD

June 29th 2022

Catherine S. Diefenbach, MD, spoke about the approval of lisocabtagene maraleucel for the treatment of relapsed/refractory large B-cell lymphoma following 1 prior therapy.

Checkpoint Inhibition in Hodgkin Lymphoma: Saving the Best for Last?

Richard J. Lin, MD;Catherine S. Diefenbach, MD

October 15th 2016

In this article we review the scientific rationale, preclinical evidence, and most recent clinical data for the use of checkpoint inhibitor therapy in patients with relapsed Hodgkin lymphoma.

Peripheral T-Cell Lymphoma: Time for a T-Cell–Centric Standard of Care

Shella Saint Fleur-lominy, MD, PhD;Catherine S. Diefenbach, MD

September 15th 2013

This is an exciting time in the treatment of PTCL, but with this opportunity comes responsibility. The challenge of how to optimize a plethora of promising new therapies for a small number of patients will drive therapeutic decision making for the foreseeable future.